SILK ROAD MEDICAL INC (SILK) Fundamental Analysis & Valuation

NASDAQ:SILK • US82710M1009

Current stock price

27.49 USD
-0.01 (-0.04%)
At close:
27.49 USD
0 (0%)
After Hours:

This SILK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SILK Profitability Analysis

1.1 Basic Checks

  • SILK had negative earnings in the past year.
  • SILK had a negative operating cash flow in the past year.
  • SILK had negative earnings in each of the past 5 years.
  • SILK had a negative operating cash flow in each of the past 5 years.
SILK Yearly Net Income VS EBIT VS OCF VS FCFSILK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -20.96%, SILK is in line with its industry, outperforming 51.87% of the companies in the same industry.
  • SILK has a Return On Equity (-36.55%) which is in line with its industry peers.
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROIC N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
SILK Yearly ROA, ROE, ROICSILK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

  • SILK's Gross Margin of 74.28% is amongst the best of the industry. SILK outperforms 85.03% of its industry peers.
  • SILK's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SILK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
SILK Yearly Profit, Operating, Gross MarginsSILK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

5

2. SILK Health Analysis

2.1 Basic Checks

  • SILK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SILK has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for SILK is higher compared to a year ago.
SILK Yearly Shares OutstandingSILK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SILK Yearly Total Debt VS Total AssetsSILK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

  • SILK has an Altman-Z score of 4.49. This indicates that SILK is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.49, SILK is doing good in the industry, outperforming 72.73% of the companies in the same industry.
  • SILK has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.49, SILK is not doing good in the industry: 64.17% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z 4.49
ROIC/WACCN/A
WACC8.47%
SILK Yearly LT Debt VS Equity VS FCFSILK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

  • SILK has a Current Ratio of 7.63. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 7.63, SILK belongs to the top of the industry, outperforming 85.56% of the companies in the same industry.
  • SILK has a Quick Ratio of 6.69. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 6.69, SILK belongs to the best of the industry, outperforming 83.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.63
Quick Ratio 6.69
SILK Yearly Current Assets VS Current LiabilitesSILK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

5

3. SILK Growth Analysis

3.1 Past

  • The earnings per share for SILK have decreased by -2.13% in the last year.
  • Looking at the last year, SILK shows a quite strong growth in Revenue. The Revenue has grown by 17.54% in the last year.
  • The Revenue has been growing by 38.63% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.87% on average over the next years.
  • The Revenue is expected to grow by 13.50% on average over the next years. This is quite good.
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SILK Yearly Revenue VS EstimatesSILK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SILK Yearly EPS VS EstimatesSILK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20

0

4. SILK Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SILK. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SILK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SILK Price Earnings VS Forward Price EarningsSILK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SILK Per share dataSILK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.37%
EPS Next 3Y3.9%

0

5. SILK Dividend Analysis

5.1 Amount

  • SILK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SILK Fundamentals: All Metrics, Ratios and Statistics

SILK ROAD MEDICAL INC

NASDAQ:SILK (9/16/2024, 8:00:02 PM)

After market: 27.49 0 (0%)

27.49

-0.01 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07
Earnings (Next)11-06
Inst Owners3.3%
Inst Owner Change0%
Ins Owners28.49%
Ins Owner Change0%
Market Cap1.12B
Revenue(TTM)191.44M
Net Income(TTM)-56.54M
Analysts49.23
Price Target22.54 (-18.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.36%
Min EPS beat(2)-9.6%
Max EPS beat(2)12.31%
EPS beat(4)3
Avg EPS beat(4)8.54%
Min EPS beat(4)-9.6%
Max EPS beat(4)23.2%
EPS beat(8)6
Avg EPS beat(8)10.47%
EPS beat(12)7
Avg EPS beat(12)1.66%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)1.28%
Max Revenue beat(2)6.4%
Revenue beat(4)3
Avg Revenue beat(4)3.97%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)10.41%
Revenue beat(8)6
Avg Revenue beat(8)3.67%
Revenue beat(12)9
Avg Revenue beat(12)2.91%
Revenue beat(16)12
Avg Revenue beat(16)2.27%
PT rev (1m)-2.14%
PT rev (3m)6.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.92%
EPS NY rev (1m)-2.69%
EPS NY rev (3m)-2.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.22%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.83
P/FCF N/A
P/OCF N/A
P/B 7.22
P/tB 7.22
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS4.71
BVpS3.81
TBVpS3.81
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -20.96%
ROE -36.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.28%
FCFM N/A
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 81.1%
Cap/Sales 1.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.63
Quick Ratio 6.69
Altman-Z 4.49
F-Score4
WACC8.47%
ROIC/WACCN/A
Cap/Depr(3y)251.08%
Cap/Depr(5y)187.13%
Cap/Sales(3y)3.05%
Cap/Sales(5y)2.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
EBIT growth 1Y-13.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.12%
EBIT Next 3Y19.7%
EBIT Next 5YN/A
FCF growth 1Y27.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.14%
OCF growth 3YN/A
OCF growth 5YN/A

SILK ROAD MEDICAL INC / SILK Fundamental Analysis FAQ

What is the fundamental rating for SILK stock?

ChartMill assigns a fundamental rating of 3 / 10 to SILK.


What is the valuation status of SILK ROAD MEDICAL INC (SILK) stock?

ChartMill assigns a valuation rating of 0 / 10 to SILK ROAD MEDICAL INC (SILK). This can be considered as Overvalued.


How profitable is SILK ROAD MEDICAL INC (SILK) stock?

SILK ROAD MEDICAL INC (SILK) has a profitability rating of 2 / 10.


How financially healthy is SILK ROAD MEDICAL INC?

The financial health rating of SILK ROAD MEDICAL INC (SILK) is 5 / 10.


What is the expected EPS growth for SILK ROAD MEDICAL INC (SILK) stock?

The Earnings per Share (EPS) of SILK ROAD MEDICAL INC (SILK) is expected to decline by -3.77% in the next year.